Brought to you by

Novartis licenses Debiopharm's Debio025 for HCV; Debiopharm regains rights
22 Jan 2015
Executive Summary
Novartis has received exclusive development, manufacturing, and marketing rights (excluding Japan) to fellow Swiss pharma developer Debiopharm's Phase IIb Debio025 (alisporivir), a first-in-class cyclophilin inhibitor for hepatitis C.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com